Doctors, Patients Often Unaware of Drug Recalls: Study

Some drug recalls involving serious and potentially life-threatening problems appear to be slipping through the cracks, with federal regulators often failing to adequately notify doctors and patients, according to the findings of a new study. 

A research letter published in the Archives of Internal Medicine points out what appear to be flaws in the FDA’s notification system for “Class I” drug recalls, which is the most serious category for recalled medications, reserved for drugs with problems that are likely to cause severe injury or death if used.

The FDA is supposed to issue notifications for Class I drug recalls through its Recall Alert System and its MedWatch adverse event reporting system. However, researchers looked at 1,700 drug recalls issued between 2004 and 2011, finding about one major recall per month. They determined that 91 of those were Class I recalls, but not all were reported.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Of the 91 Class I recalls, the Recall Alert System only issued notices for 55 of them. MedWatch did somewhat better, issuing notices for 18 of the remaining 36 that were classified as Class I. That leaves another 18, about one-fifth, that were not reported to doctors by any FDA system.

FDA officials were at a loss to explain the discrepancies, but indicate that they are working on improving their reporting systems, according to a report by Reuters Health.

Researchers note that not only is incompleteness of the warnings a problem, but doctors also may have trouble distinguishing which ones are important and which are not, since both systems try to report every drug recall. For example, veterinary drug recalls are reported in the same manner as Class I drugs, which may pose lethal risks for humans.

“Equally problematic, the Class I recalls that are communicated through the Recall Alert System become buried in a system that is also used for recalls that have little or no bearing on patient care,” the researchers determined. “It may be difficult for providers who subscribe to and rely on these alerting systems to identify those recalls that are of particular importance.”

The researchers called for a comprehensive new strategy for ensuring that health care providers are duly notified when there are clinically important drug recalls.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Depo-Provera Brain Tumor Warnings Added to Drug Label in Europe, But Not In U.S.
Depo-Provera Brain Tumor Warnings Added to Drug Label in Europe, But Not In U.S. (Posted 2 days ago)

A recently filed Depo-Provera lawsuit questions why Pfizer updated the drug label in Europe, to warn about the risk of meningioma brain tumors, but failed to provide the same Depo-Provera warnings to U.S. consumers and doctors.

Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week
Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week (Posted 4 days ago)

U.S. District Judge presiding over all federal hair relaxer lawsuits will meet with lawyers involved in the litigation on Thursday, to discuss the status of the claims and when to move forward with bellwether cases.